Liens rapides
Liens des membres
Sustainable Access to Plasma-Derived Medicinal Products: A Resilience-Informed Approach to Cost-Containment
Sustainable Access to Plasma-Derived Medicinal Products: A Resilience-Informed Approach to Cost-Containment
PPTA Announces Changes to Global Executive Board and European Board Leadership
PPTA Announces Changes to Global Executive Board and European Board Leadership
Catégories
Fiches d'information
Les fiches d'information fournissent des informations supplémentaires sur l'industrie mondiale des protéines plasmatiques thérapeutiques.
Publications et présentations
Discover the main highlights of our industry in our latest publications.
Ressources pour les patients
Explorez les ressources de PPTA pour les patients intéressés par les thérapies aux protéines plasmatiques.
Rapports des parties prenantes
Apprenez-en plus en accédant à la collection de rapports de l'industrie.
Actualités et communiqués de presse
Restez au courant de l'actualité et des événements de l'Association.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Nov 10, 2026
Sustainable Access to Plasma-Derived Medicinal Products: A Resilience-Informed Approach to Cost-Containment
All
PPTA Statements
https://cdn.prod.website-files.com/6916f1777886bb3b9377a752/6af3642bc58c382cacfcdb31_PPTA_2680%20Cost%20Containment%20Position%20PaperV2.pdf
Nov 10, 2026
Sustainable Access to Plasma-Derived Medicinal Products: A Resilience-Informed Approach to Cost-Containment
All
PPTA Statements
https://cdn.prod.website-files.com/6916f1777886bb3b9377a752/6af3642bc58c382cacfcdb31_PPTA_2680%20Cost%20Containment%20Position%20PaperV2.pdf
Nov 10, 2026
Sustainable Access to Plasma-Derived Medicinal Products: A Resilience-Informed Approach to Cost-Containment
All
Publication
https://cdn.prod.website-files.com/6916f1777886bb3b9377a752/6af3642bc58c382cacfcdb31_PPTA_2680%20Cost%20Containment%20Position%20PaperV2.pdf
Nov 10, 2026
Sustainable Access to Plasma-Derived Medicinal Products: A Resilience-Informed Approach to Cost-Containment
All
Publication
https://cdn.prod.website-files.com/6916f1777886bb3b9377a752/6af3642bc58c382cacfcdb31_PPTA_2680%20Cost%20Containment%20Position%20PaperV2.pdf
Oct 28, 2026
Maintaining Immunoglobulins on the Union List of Critical Medicines to Safeguard Patient Access
As the review of the Union List of Critical Medicines (ULCM) approaches its conclusion, the Plasma Protein Therapeutics Association (PPTA) strongly supports maintaining human normal immunoglobulins (IG) on the Union list1 as they are lifesaving, irreplaceable treatments of human origin facing ongoing supply challenges. Maintaining IG on the Union list supports the EU’s broader agenda to strengthen the resilience, security and sustainability of medicines supply as well as safeguard reliable access for patients across Europe.
All
PPTA Statements
https://cdn.prod.website-files.com/6916f1777886bb3b9377a752/6ae22ea3cac65bcf56c49109_FINAL%20PPTA%20statement%20on%20Union%20List%20of%20Critical%20Medicines_28.10.2026.pdf
Oct 28, 2026
Maintaining Immunoglobulins on the Union List of Critical Medicines to Safeguard Patient Access
As the review of the Union List of Critical Medicines (ULCM) approaches its conclusion, the Plasma Protein Therapeutics Association (PPTA) strongly supports maintaining human normal immunoglobulins (IG) on the Union list1 as they are lifesaving, irreplaceable treatments of human origin facing ongoing supply challenges. Maintaining IG on the Union list supports the EU’s broader agenda to strengthen the resilience, security and sustainability of medicines supply as well as safeguard reliable access for patients across Europe.
All
PPTA Statements
https://cdn.prod.website-files.com/6916f1777886bb3b9377a752/6ae22ea3cac65bcf56c49109_FINAL%20PPTA%20statement%20on%20Union%20List%20of%20Critical%20Medicines_28.10.2026.pdf
Aucun résultat n'a été trouvé